HC Wainwright Increases Earnings Estimates for GH Research

GH Research PLC (NASDAQ:GHRS) – Equities research analysts at HC Wainwright boosted their FY2029 EPS estimates for GH Research in a report issued on Tuesday, March 4th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of $0.13 per share for the year, up from their previous forecast of $0.10. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share.

A number of other research analysts also recently issued reports on GHRS. Stifel Nicolaus upped their price target on GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Canaccord Genuity Group reduced their target price on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Finally, Cantor Fitzgerald started coverage on GH Research in a research note on Thursday, February 13th. They issued an “overweight” rating and a $14.00 price target for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $30.60.

GH Research Stock Up 10.9 %

NASDAQ:GHRS opened at $10.41 on Thursday. The firm has a market capitalization of $541.61 million, a P/E ratio of -13.18 and a beta of 0.93. GH Research has a 52 week low of $6.00 and a 52 week high of $20.50. The company has a fifty day moving average of $10.66 and a 200 day moving average of $9.19.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. RA Capital Management L.P. boosted its holdings in shares of GH Research by 1.3% during the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock valued at $44,734,000 after acquiring an additional 85,000 shares during the last quarter. Geode Capital Management LLC boosted its holdings in GH Research by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock worth $508,000 after purchasing an additional 3,092 shares during the last quarter. Diadema Partners LP purchased a new position in shares of GH Research in the 4th quarter worth $711,000. Lynx1 Capital Management LP increased its position in GH Research by 15.8% during the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock valued at $34,013,000 after acquiring an additional 663,100 shares during the last quarter. Finally, Northern Trust Corp boosted its position in GH Research by 26.8% in the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock worth $286,000 after purchasing an additional 8,641 shares during the last quarter. 56.90% of the stock is owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).